FME.DE·Healthcare
Fresenius Medical Care quarter with profit surge, strong cost-cutting program – but the cautious 2026 outlook significantly weighs on the…
HIMS·Healthcare
Hims & Hers quarter shows strong growth but weak outlook, GLP-1 dispute, and SEC risks – what this means for…
LLY·Healthcare·Pharma
Eli Lilly Weight Loss: Stock jumps after weaker CagriSema data from Novo Nordisk – what does the rally mean for…
NVO·Healthcare·Pharma
Novo Nordisk CagriSema misses against Tirzepatide in REDEFINE-4; stock plunges 15% in pre-market – what this means for investors.
MRK.DE·Healthcare
Merck dividend strategy in focus: Can the pipeline cushion the Keytruda patent cliff starting in 2028 for dividend hunters?